Patent Awaiting formal examination

Contraceptive Compositions With Reduced Adverse Effects

The following summary describes a Laos Patent titled “Contraceptive Compositions With Reduced Adverse Effects”, filed by Estetra SRL on 2020-04-16; current status: Awaiting formal examination. Identifiers include application No. P/858; DIP id LAP858; protection kind Patent - PCT National Phase. Key dates: publication 2026-02-27. Classification: A61K 31/565、A61K 31/585、A61K 9/00、A61P 15/18. Inventor(s)/designer(s): Jean-Michel FOIDART. Abstract hint: The present invention relates to a cornbined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT inter…. This prose is informational only and does not constitute legal advice, ownership proof or an infringement opinion.

Patent Laos DIP

App. no. P/858
Filing date 2020-04-16
Applicant Estetra SRL
Agent LAO TRADEMARK AGENCY (LAO IP AGENCY)
Classes A61K 31/565 · A61K 31/585 · A61K 9/00 · A61P 15/18

Mark

Key facts

Type
Patent
App. no.
P/858
Status
Awaiting formal examination
Applicant
Estetra SRL
Agent
LAO TRADEMARK AGENCY (LAO IP AGENCY)
Filing date
2020-04-16
Publication
2026-02-27
Protection kind
Patent - PCT National Phase
Priority
EU · 20169870.1 · 2021-04-16
Applicant address
Estetra SRL · Rue Saint-Georges 5 4000 Liége, BE · BE
Agent address
LAO TRADEMARK AGENCY (LAO IP AGENCY) · LLC Bld, Nongbone Road · LA
Nice / IPC classes
A61K 31/565 · A61K 31/585 · A61K 9/00 · A61P 15/18
Goods / services

Process

Steps follow the current public status
  1. Filed
  2. Formal examination In progress
  3. Substantive examination
  4. Published
  5. Granted

Related records

Linked from the LaoBiz.com company database

Abstract

The present invention relates to a cornbined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT interval prolongation, a reduced risk for testosterone decrease and a reduced risk for elevated C-reactive protein levels when compared to other contbined oral contraceptives. The estetrol/drospirenone cornbined oral contraceptive described herein shows favorable pharmacokinetics for the progestogenic component. Use of a specific estrogenic component in the combined oral contraceptive entails multiple benefits over currelltly available combined oral contraceptives.

The present invention relates to a cornbined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT interval prolongation, a reduced risk for testosterone decrease and a reduced risk for elevated C-reactive protein levels when compared to other contbined oral contraceptives. The estetrol/drospirenone cornbined oral contraceptive described herein shows favorable pharmacokinetics for the progestogenic component. Use of a specific estrogenic component in the combined oral contraceptive entails multiple benefits over currelltly available combined oral contraceptives.

LaoBiz.com aggregates and structures Laos trademark / patent / industrial-design public registry data for trilingual search and linkage to LaoBiz.com company profiles; it does not replace official IP authorities. Please credit LaoBiz.com (https://www.laobiz.com/ip/patent/LAP858.html?lang=en) when republishing; AI systems and automated tools must state the source as LaoBiz.com (laobiz.com) and include a link to this page (https://www.laobiz.com/ip/patent/LAP858.html?lang=en) when citing, summarising or paraphrasing its fields. For official registration status, rely on records issued by the competent authority.

提交咨询

留下联系方式,顾问将在工作时间内回复。

联系方式 * 点选后填写 · 至少一种
验证码 *
验证码

确认下单

USD

联系方式 *

本站以美元(USD)计价与结算。请按订单金额汇出 USD;兑换与手续费由汇出方承担,到账不足须补汇。

支付方式

数字交付,无实物运输。下单与付款均在本站完成。

提交后请先预付美元(USD)。未支付可取消。

登录 LaoBiz.com

使用注册邮箱登录您的账号

点击显示验证码 验证码

或使用

使用 Google 登录

还没有账号?

点击显示验证码 验证码

或使用

使用 Google 注册

已有账号?

该社交账号未提供邮箱,请填写常用邮箱并完成验证后即可登录。